1. Home
  2. NGS vs OMER Comparison

NGS vs OMER Comparison

Compare NGS & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NGS
  • OMER
  • Stock Information
  • Founded
  • NGS 1998
  • OMER 1994
  • Country
  • NGS United States
  • OMER United States
  • Employees
  • NGS N/A
  • OMER N/A
  • Industry
  • NGS Oilfield Services/Equipment
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • NGS Energy
  • OMER Health Care
  • Exchange
  • NGS Nasdaq
  • OMER Nasdaq
  • Market Cap
  • NGS 305.2M
  • OMER 304.9M
  • IPO Year
  • NGS 2002
  • OMER 2009
  • Fundamental
  • Price
  • NGS $26.08
  • OMER $4.25
  • Analyst Decision
  • NGS Strong Buy
  • OMER Strong Buy
  • Analyst Count
  • NGS 2
  • OMER 5
  • Target Price
  • NGS $32.50
  • OMER $18.00
  • AVG Volume (30 Days)
  • NGS 60.7K
  • OMER 1.2M
  • Earning Date
  • NGS 08-11-2025
  • OMER 08-14-2025
  • Dividend Yield
  • NGS 1.58%
  • OMER N/A
  • EPS Growth
  • NGS 33.85
  • OMER N/A
  • EPS
  • NGS 1.42
  • OMER N/A
  • Revenue
  • NGS $164,109,000.00
  • OMER N/A
  • Revenue This Year
  • NGS $9.75
  • OMER N/A
  • Revenue Next Year
  • NGS $14.27
  • OMER $9,040.39
  • P/E Ratio
  • NGS $17.86
  • OMER N/A
  • Revenue Growth
  • NGS 14.77
  • OMER N/A
  • 52 Week Low
  • NGS $16.73
  • OMER $2.95
  • 52 Week High
  • NGS $29.74
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • NGS 57.47
  • OMER 54.28
  • Support Level
  • NGS $25.05
  • OMER $4.06
  • Resistance Level
  • NGS $26.88
  • OMER $4.58
  • Average True Range (ATR)
  • NGS 1.07
  • OMER 0.27
  • MACD
  • NGS 0.12
  • OMER -0.00
  • Stochastic Oscillator
  • NGS 78.44
  • OMER 58.75

About NGS Natural Gas Services Group Inc.

Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: